Evogene Ltd.
EVGN
$0.97
-$0.0255-2.56%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 178.72% | 39.76% | -12.42% | 708.37% | 708.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 178.72% | 39.76% | -12.42% | 708.37% | 708.37% |
| Cost of Revenue | 89.70% | 16.49% | 9.34% | 325.83% | 325.83% |
| Gross Profit | 375.56% | 95.34% | -39.19% | 841.04% | 841.04% |
| SG&A Expenses | -10.65% | -9.80% | -19.89% | -2.90% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.62% | -18.05% | 84.74% | 5.12% | 5.12% |
| Operating Income | 33.57% | 22.83% | -101.69% | 41.06% | 41.06% |
| Income Before Tax | 100.03% | 22.86% | -94.41% | 46.03% | 46.03% |
| Income Tax Expenses | 275.00% | -95.24% | -108.89% | -200.00% | -200.00% |
| Earnings from Continuing Operations | 99.93% | 23.05% | -92.02% | 46.14% | 46.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -41.30% | -25.03% | -10.57% | -120.36% | -120.36% |
| Net Income | 106.47% | 22.84% | -120.18% | 39.12% | 39.12% |
| EBIT | 33.57% | 22.83% | -101.69% | 41.06% | 41.06% |
| EBITDA | 35.76% | 24.40% | -121.74% | 45.41% | 45.41% |
| EPS Basic | 104.81% | 36.88% | -79.47% | 48.71% | 48.71% |
| Normalized Basic EPS | 102.45% | 36.64% | -198.82% | 44.48% | 44.48% |
| EPS Diluted | 104.81% | 36.88% | -79.47% | 48.71% | 48.71% |
| Normalized Diluted EPS | 102.45% | 36.64% | -198.82% | 44.48% | 44.48% |
| Average Basic Shares Outstanding | 34.34% | 22.25% | 22.68% | 18.70% | 18.70% |
| Average Diluted Shares Outstanding | 34.34% | 22.25% | 22.68% | 18.70% | 18.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |